Why Peregrine Earnings Are Stuck in the Red

Peregrine Pharmaceuticals (NASDAQ: PPHM  ) will release its latest quarterly report on Thursday, but investors are still cautious about the small biotech's future prospects. With the stock still hovering at low levels, it's clear that shareholders want to see Peregrine earnings turn positive a lot sooner than is likely.

Peregrine Pharmaceuticals has chosen to concentrate on cancer, as well as hepatitis C and other viral infections, with its antibody-based treatments seeking to help the body's own defenses work to rid patients of their diseases and their ill effects. Yet a setback last year hurt Peregrine's future prospects, leaving investors uncertain what the next step forward is for the company. Let's take an early look at what's been happening with Peregrine Pharmaceuticals over the past quarter and what we're likely to see in its quarterly report.

Stats on Peregrine Pharmaceuticals

Analyst EPS Estimate

($0.06)

Year-Ago EPS

($0.10)

Revenue Estimate

$3.57 million

Change From Year-Ago Revenue

73%

Earnings Beats in Past 4 Quarters

4

Source: Yahoo! Finance.

How will Peregrine earnings do this quarter?
Analysts haven't really changed their views about Peregrine's earnings prospects in the past few months. They've held their April-quarter estimates unchanged and narrowed their fiscal 2014 estimates by a single penny per share. The stock has been in a similar holding pattern, with shares up just 3% since early April.

The big news for Peregrine came in May, when the company announced that it was starting a phase 3 trial for its bavituximab treatment for non-small-cell lung cancer. Unfortunately for shareholders, the 19% surge in the stock price that day didn't hold up, as investors realized that starting a trial is a lot different from having a successful trial. Moreover, with Peregrine's problems in analyzing the treatment's phase 2 results, investors have to be a little skeptical about bavituximab's prospects before another trial confirms the treatment's effectiveness.

Early last month, Peregrine got a little more validation when it released new data showing a survival increase of 4.4 months for non-small-cell lung cancer patients compared to the study's control. Shares again moved up temporarily, but then fell back in subsequent days as investors again realized that they'll have to wait for the new study's results to be sure of the treatment's effectiveness. Then just a couple weeks ago, Peregrine released further data that showed little advantage from the drug over using other treatments to fight lung cancer, and that sent the stock plunging about 25%.

The problem Peregrine faces is that much larger competitors are fighting to find their own successful treatments. For instance, Celgene (NASDAQ: CELG  ) did a trial testing its Abraxane treatment for pancreatic cancer that had a better hazard ratio than bavituximab and also showed clearer signs of statistical significance. Yet even big companies have had trouble getting cancer treatments approved, with Sanofi (NYSE: SNY  ) having failed to demonstrate favorable benefits in the non-small-cell lung cancer arena and with Eli Lilly (NYSE: LLY  ) and its Alimta treatment not producing better results, either.

In the Peregrine earnings release, watch for the company to give updates on its long-term strategy going forward. With little revenue, cash burn is an important consideration as investors need to assess the risk of further financing needs diluting their investment in Peregrine stock.

The wildcard that is affecting biotech stocks of all sizes is Obamacare, which will undoubtedly have far-reaching effects throughout the health-care industry. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio could be affected. Click here to read more. 

Click here to add Peregrine Pharmaceuticals to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 09, 2013, at 1:58 PM, BSDetector wrote:

    I defended this company for 8 months. In conclusion, I have found them to be quite adept at carrot dangling....nothing more.

    Far better opportunities available in the market place. Don't waste your time with PPHM other than a quick day trade.

    Ex PPHM Long

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2527876, ~/Articles/ArticleHandler.aspx, 10/22/2014 10:07:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 16,636.35 21.54 0.13%
S&P 500 1,946.09 4.81 0.25%
NASD 4,428.11 8.64 0.20%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/22/2014 9:48 AM
PPHM $1.48 Down +0.00 +0.00%
Peregrine Pharmace… CAPS Rating: **
CELG $95.84 Up +0.87 +0.92%
Celgene CAPS Rating: *****
LLY $65.23 Up +0.55 +0.85%
Eli Lilly & Co. CAPS Rating: ****
SNY $53.00 Up +0.85 +1.62%
Sanofi (ADR) CAPS Rating: *****

Advertisement